Iktos leverages AI and robotics to transform drug discovery, integrating Generative AI with automated synthesis and testing to accelerate the development of new treatments to improve patient care.

Iktos

Biotechnology Research

Makya™

iktos | 7,435 followers on LinkedIn. Artificial intelligence for new drug design | We are Iktos. A start-up company specializing in the development of proprietary artificial intelligence technologies and software for ligand-based and structure-based de novo drug design focusing on multi parametric optimization.

Our de novo design algorithm is based on deep generative models with reinforcement learning.

Chief Financial Officer in Life Sciences Industry

Stéphane MILOT

AI-driven drug discovery to improve human lives

Philip Laut

SVP, Head Drug Discovery

Alexis Denis

Investment Principal at Debiopharm Innovation Fund | Venture Capital | Digital Health, TechBio & AI

Vincent Lepreux

iktos

(🇬🇧 message below) LinkedIn コミュニティーの皆様こんにちは！ イクトスAPACチームです 🙂 11月20日から京都で開催される第41回メディシナルケミストリーシンポジウムに参加します。 ご参加予定の方は是非弊社の企業展示スペースにお立ち寄りください。第６会場東館２階セミナー室、ブース番号は３０です。 最終日の11月22日（金）にはランチョンセミナーにてCSOのQuentinが講演を行います。 イクトスのAI・自動化技術がどのように創薬研究を加速させるのか、弊社の事例を用いながらご紹介いたします。イクトスについてご存知の方もそうでない方も是非ご参加ください！ 当日会場で皆様にお会いできるのを心待ちにしています。 🌟 The Iktos team will be participating in the 41st Medicinal Chemistry Symposium in Kyoto 🇯🇵 November 20-22. Quentin Perron , Hideyoshi Fuji , Victoire M. L. Cachoux and Mizuki Ebihara look forward to meeting with you! If you plan to attend, please stop by our booth #30. They will be happy to discuss your drug discovery project together and highlight how our GenAI and Robotics platform can support it. 📢 Also, do not miss our CSO Quentin Perron’s lecture at the luncheon seminar. He will introduce how iktos ’ AI and automation technology accelerates drug discovery research using our company's case studies. ✨ Whether you already know about Iktos or not, please come and join us! 👉 https://lnkd.in/gmxPqJg5 #drugdiscovery #PharmaTech #InnovativeTherapies #artificialintelligence #Makya #Spaya #robotics

✨ Meet Dr. Dominique Bridon , a seasoned leader in pharmaceutical innovation ✨ We are excited to welcome him to our newly appointed Scientific Advisory Board! His extensive expertise in drug development will be instrumental in advancing Iktos’ pipeline of AI-first drug candidates. 🌟 🔬 With over 30 years of experience, Dr. Bridon has led drug development from early research through clinical studies across a wide range of therapeutic areas, including oncology, infectious diseases, metabolic, and cardiovascular disorders. His work has been instrumental in bringing innovative therapies to patients and advancing pharmaceutical science. 🚀 💼 Currently the CSO of Evexta Bio , a precision oncology start-up, Dr. Bridon has held senior management roles at Abbott , Ipsen , and EpiVax, Inc. , as well as in several biotechs acquired by larger players, including Optivia, Enobia Pharma , and Syntaxin. Additionally, he co-founded ConjuChem , which went public on the Toronto Stock Exchange and was later acquired. 🧬 💡 His deep understanding of the entire drug development lifecycle, combined with his strategic leadership and entrepreneurial acumen, will help Iktos mature and expand our pipeline, pushing the boundaries of AI-first drug discovery. We are honored to have him on board as we continue to drive innovation in drug discovery through GenAI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eW5pZe-7 #DrugDiscovery #PharmaTech #ArtificialIntelligence iktos

🚀 We’re thrilled to announce that our team will be attending the 9th #Investival Showcase as part of Jefferies Healthcare Week! Our CEO, Yann Gaston-Mathe , along with Marion Laguette , will be in London from November 18th to 21st. Don’t miss the opportunity to connect with them! 🤝 With over 60 small molecule projects spanning most therapeutic areas, iktos is at the forefront of de novo drug design, driven by our proprietary and powerful technologies. 💡 Our platform accelerates research projects from hit discovery to PCC in under 24 months—significantly faster than the traditional 3-5 years industry timeline. ⏱️ ✨ Join us to discover more about our vision for drug discovery and how we aim to revolutionize the field through GenAI, Robotics, and our growing development pipeline. 🌟 https://lnkd.in/eP7Cz4CS #Investment #biotech #PharmaTech #techbio #DrugDiscovery #ArtificialIntelligence

✨ Meet Dr. Thierry Masquelin , a visionary in drug discovery and robotics ✨ We are thrilled to welcome him to our newly appointed Scientific Advisory Board! His extensive expertise in robotics and automation will be instrumental in advancing iktos ’ AI-driven drug discovery platform. 🌟 🔬 With over 30 years of experience, Dr. Masquelin is renowned for creating the Lilly Life Science Studio ( #L2S2 )—a cutting-edge automated facility that transformed molecular design, synthesis, and biological testing. He also developed the world’s first Automated Synthesis and Purification Lab (ASPL), significantly streamlining drug discovery by integrating scientific functions and reducing cycle times. 🚀 🎓 Dr. Masquelin holds a PhD from the Université de Haute-Alsace - UHA and currently serves as COO of the ASPIRE initiative at the National Center for Advancing Translational Sciences (NCATS) . After senior roles at Eli Lilly and Company , he joined Recursion as Senior Director, where he developed a unified, multi-disciplinary platform to consolidate early drug discovery phases. 🧬 💼 His leadership in robotics and automation, paired with his experience in medicinal chemistry, will help position Iktos as a global leader in AI-first drug discovery. We’re excited to have Dr. Masquelin on board as we push the boundaries of innovation in drug discovery through AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

AI platforms are uniquely positioned to address unmet patient needs by driving first-in-class therapies! This insightful analysis by Luka Jelcic and Andrii Savytskyi , provides a valuable overview of the novelty of targets pursued by AI-first companies. At iktos , our pipeline is dedicated to advancing therapies that tackle emerging, less-explored targets. With the power of #GenAI and #robotics , we’re identifying novel chemical matter and accelerating H2L processes to open up new therapeutic possibilities. With experience across over 60 targets, we’ve focused our internal pipeline on oncology, inflammation, and autoimmune diseases—fields in need of innovative solutions that offer safer, more tolerable therapies for patients with chronic conditions. 👉 We’re attending #BIOEurope this week; reach out if you’d like to connect! #AIDrugDiscovery #Innovation #NovelTargets #PatientNeeds #PharmaTech #Iktos

🤝 Proven AI partner across 60+ targets! With experience in most therapeutic areas and a current internal pipeline focused on oncology, inflammation, and autoimmune diseases, iktos is ready to partner with you. Let’s leverage our GenAI and robotics platform to accelerate your drug discovery! 🚀 Connect with us at Proventa International ’s Medicinal Chemistry Strategy Meeting. 🌟 Avirup Bose and Matthew Medcalf will be there to explore partnership opportunities and discover how we can accelerate your R&D together! 🔬✨ 👉 To learn more : https://lnkd.in/gx_uvacq #Iktos #drugdiscovery #artificialintelligence #PharmaPartnership #robotics #Makya #Spaya

🌟 iktos is excited to participate in the upcoming Automated Synthesis Forum🇬🇧 Franck Le Vaillant , our Deputy Lab Head, will showcase how we are developing an autonomous drug discovery platform with a strong focus on our AI-driven approach to accelerate the synthesis of bioactive molecules. You won’t want to miss his talk! He will be joined by Nicolas Martin, PhD , our Director of European Business Development. They are both eager to connect with you at the forum to discuss how GenAI & Robotics can enhance your drug discovery process. 🤖💡 Looking forward to seeing you there! 👋 👉 https://lnkd.in/enUktD2a #robotics #artificialintelligence #PharmaTech #drugdiscovery #PharmaPartnership #Makya #Spaya #ASF2024

✨ Meet Friedrich Rippmann , PhD a visionary leader in AI-driven drug discovery ✨ We are thrilled to welcome him to our newly appointed Scientific Advisory Board! His pioneering work in integrating AI into drug discovery will be instrumental in advancing Iktos’s platform and accelerating pharmaceutical partnerships. 🌟 🔬 He is a seasoned drug discovery professional and former Director of Computational Chemistry and Biologics at Merck Group . As an early and visionary adopter of AI in pharma, he led transformative efforts to integrate AI and machine learning into drug discovery, revolutionizing how computational chemistry is applied across the pharmaceutical industry. His work on discovering and optimizing lead compounds and predicting molecular properties has had a lasting impact. 🚀 🎯 His extensive expertise in structure-based drug design and protein-ligand interactions has been critical in optimizing therapeutic candidates, while his current role as Director at CombinAble.AI reflects his ongoing commitment to innovation. There, he is driving the vision to make antibody candidates developable and manufacturable through novel proprietary computational methods. 🧬💡 💼 As a member of iktos ’ Scientific Advisory Board, Friedrich Rippmann will bring his deep expertise in computational modeling and its integration into pharma, playing a pivotal role in enhancing our AI-first drug discovery partnerships. We are excited to have his guidance as we continue to transform drug discovery with AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

📖 Don’t miss the latest editorial in the Journal of Medicinal Chemistry from American Chemical Society . Weijun Xu explores how the growing synergy between Computer-Aided Drug Design (CADD) and Artificial Intelligence in Drug Discovery (AIDD), are unlocking complex therapeutic challenges and paving the way for next-gen medicines 💊. 💻 The article gives an up-to-date look at computational innovations—from deep learning to advanced molecular docking—and highlights key players like Insilico Medicine , Exscientia , Recursion , iktos , and more. 🌟 A perfect Friday read on the trends shaping the future of pharma, where AI-driven innovation is just getting started! ⚡️ 🔗 Read more: https://lnkd.in/ehtA3VeD #CADD #AIDD #ArtificialIntelligence #DrugDiscovery #PharmaTrends ACS Publications #JournalOfMedicinalChemistry

✨ Meet Dr. Laurent Debussche , first-in-human drug discovery expert✨ We are excited to welcome him to our new Scientific Advisory Board! His expertise will be invaluable in accelerating our AI-driven drug discovery pipeline to address unmet patient needs. 🌟 🔬 With over 35 years of experience in oncology R&D, Dr. Debussche has held senior leadership roles at major pharmaceutical companies. Most recently, he served as VP Global Head of Oncology Research at Sanofi , where he advanced several first-in-human oncology drug candidates. His work spans a wide range of technologies, including small molecules, monoclonal antibodies (MAbs), nanobodies, antibody-drug conjugates (ADCs), cell engagers, and more. 🚀 🎓 Currently, Dr. Debussche serves as CEO of DLog Consulting, where he provides expert guidance in oncology drug development and strategic R&D leadership. He has co-authored over 60 international scientific publications and holds several dozen patents. 🏅 With a PhD in Molecular Biology from Pierre and Marie Curie University , he has led innovative research initiatives throughout his career, addressing unmet medical needs. 💡 His deep expertise in advancing first-in-human targets to clinical development will be key to accelerating iktos ’s AI-first drug discovery pipeline. We are delighted to have Dr. Debussche on board as we continue our mission to revolutionize drug discovery through AI and Robotics. 📢 Read the Press Release here: https://lnkd.in/eGtCq4HM #DrugDiscovery #PharmaTech #ArtificialIntelligence

IPhone / Mobile Compatible

Viewport Meta

Domain Not Resolving

Google Tag Manager

Apple Mobile Web Clips Icon

DNSSEC

Content Delivery Network

Organization Schema

reCAPTCHA

Apple Mobile Web App Capable

Senior Vice President, Head of US Operations and Business Development

Alessandro Monge

Vice President, Head of Business Development EU, RoW

Sree Vadlamudi

Marketing and Product

Marion Laguette

Sales and Support

Mac Monson

Operations

Noa Berkovich

Marketing and Communications Manager

Payash Bahuguna

Engineering

Anna Kriukova

Information Technology

Brian Atwood

Clarisse Descamps

Dara Phonekeo

SVP, Head of Drug Discovery

Nicolas Do Huu

Chief AI Officer, Co-founder

Yann Gaston-Mathe

CEO & Co-Founder

Avirup Bose

Chief Business Officer

Quentin Perron

CSO & Co-Founder

France Biotechnology Companies

Ile-de-France Early Stage Companies With More Than $1M in Revenue

Paris Companies With More Than 50 Employees

France Early Stage Companies

Iktos is a French scale-up company specializing in artificial intelligence and robotic solutions applied to research in medicinal chemistry and new drug design. Iktos’ proprietary and innovative generative AI solution enables the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology through the SaaS software platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, and through strategic collaborations with pharma companies where Iktos mobilizes its unique platform and leading-edge capabilities to expedite small molecule drug discovery for the benefit of its partners. Iktos has also developed Iktos Robotics, a unique AI-driven synthesis automation platform that dramatically accelerates the Design-Make-Test-Analyze cycle in drug discovery and is developing its own pipeline of drug candidates targeting oncology and auto-immune and inflammatory diseases. In March 2023, Iktos completed a 15.5M€ Series A financing round co-led by M Ventures and Debiopharm Innovation with contribution by Omnes Capital. In July 2024, Iktos announced the acquisition of Synsight, thereby complementing its Chemistry AI platform with a groundbreaking biology platform for the discovery of new drugs targeting Protein-Protein Interactions (PPI) and RNA-Protein Interactions (RPI).

Debiopharm Innovation Fund

M Ventures

Series A - Iktos

Debt Financing - Iktos

Seed Round - Iktos

Non Equity Assistance - Iktos

Computer and Software Products and Electrical and Scientific Products

Paris

Ile-de-France

France

Europe

Iktos acquires Synsight, a life sciences technology company

Iktos acquires Synsight, a life sciences technology company specializing in protein-protein and RNA-protein interactions-targeted drug discovery

Italfarmaco and Iktos collaborate to develop HDAC inhibitors for noncancer indications

Iktos announces the appointment of Roman Fleck as Chairman of the Board

A SaaS platform for AI-driven de novo drug design, focusing on Multi-Parametric Optimization (MPO) to design novel compounds.

An AI-driven synthetic planning technology that discovers and prioritizes synthetic routes, ending with commercially available building blocks.

Technology that combines docking with active learning to improve the efficiency of virtual screening in drug discovery.

Provides a synthetic accessibility score for thousands of molecules, facilitating the integration of Spaya's technology into existing workflows.

Venezuela

South America

India

Asia

Japan

South Africa

Africa

Switzerland

Iktos leverages AI and robotics to transform drug discovery, integrating generative AI with automated synthesis and testing to accelerate the development of new treatments.

news impact assignment basic	general
public peers	general	Nov 11, 2024 6:36 PM	0a4934fe
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 11, 2024 6:36 PM	d40dc1f7
crunchbase trigger	general	Nov 27, 2024 12:50 PM	1b649471
crunchbase profile	general	Nov 27, 2024 4:55 PM	a332127b
li profile	general	Nov 11, 2024 6:36 PM	c4782984
translate crunchbase fundingrounds	general	Nov 27, 2024 6:24 PM	80b4259a
peers	general	Nov 11, 2024 6:36 PM	5086151f
news basic	general	Nov 11, 2024 6:36 PM	f8cf0334
bundesanzeiger	filings
financials download nd	financials
private financials	financials

IKTO

COM:IKTOS

Iktos